Physician profile
Jacob John
NPI 1417427543
$1,448.50
in general payments reported to CMS, 2019-2025
25 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $545 · 2023: $298 · 2024: $199 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $650.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $285.57 | 2021-2024 | Ozempic, Rybelsus |
| Preventric Diagnostics, INC. | $255.26 | 2022 | |
| Dexcom, INC. | $111.98 | 2023-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $106.85 | 2021-2025 | |
| Exact Sciences Corporation | $106.45 | 2023-2025 | Cologuard Collection Kit |
| Mannkind Corporation | $88.11 | 2022-2023 | Afrezza |
| Xeris Pharmaceuticals, INC. | $50.07 | 2021-2023 | Gvoke Hypopen |
| Agile Therapeutics, INC. | $47.65 | 2021-2022 | |
| Amgen INC. | $46.97 | 2023-2024 | Otezla, Repatha |
| Lilly USA, LLC | $38.98 | 2021-2022 | |
| Lundbeck LLC | $38.52 | 2023-2024 | Rexulti |
| Si-Bone, INC. | $32.40 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $29.77 | 2022-2023 | Rexulti |
| Horizon Therapeutics Plc | $22.61 | 2023 | Krystexxa |
| Roche Diabetes Care, INC. | $20.80 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.28 | 2025 | |
| Abbvie INC. | $20.14 | 2022 | |
| Seqirus USA INC | $17.84 | 2025 | Flucelvax, Fluad |
| Scilex Pharmaceuticals INC. | $17.49 | 2024 | |
| Esperion Therapeutics, INC. | $17.08 | 2021 | |
| Amarin Pharma, INC. | $16.63 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.49 | 2022 | |
| Redhill Biopharma INC. | $15.67 | 2021 | |
| Sanofi Pasteur INC. | $12.88 | 2022 | |
| Biogen, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.